Skip to main contentLast updated: 05-Nov-2026
Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Intestine Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
When a small bowel cancer has spread, medicines lead the treatment. The choice of medicine depends on the type of tumour. There is no single treatment for “metastatic small bowel cancer”.
An adenocarcinoma is treated with chemotherapy, and a tumour test can open the door to immunotherapy. A GIST is controlled for years with daily tablets. A neuroendocrine tumour grows slowly and has several options, including surgery. Lymphoma is treated with drugs, with the aim of remission.
Surgery has a clear but different role in each type. The first step is always the same. Confirm the type with a biopsy and the right tumour tests. Then choose the drug.
For the full picture of how these cancers are treated here, read our small bowel cancer treatment page. This post explains the plan when the cancer has already spread.
Four very different tumours grow in the small bowel. They share a place in the body and little else. Each has its own medicine, its own use of surgery and its own outlook.
| Tumour type | Usual first treatment | Role of surgery | What to expect |
|---|---|---|---|
| Adenocarcinoma | Chemotherapy; immunotherapy if a tumour test allows | Selected patients with a few deposits; relief of blockage or bleeding | Serious, but treatment can control it for a time |
| GIST | Imatinib tablets, chosen by gene test | Removing leftover or single resistant deposits while on tablets | Often controlled for years |
| Neuroendocrine tumour | Injections that slow the tumour; targeted radiation if it grows | Removing the bowel tumour and reducing liver deposits | Often many years |
| Lymphoma | Drug treatment by blood cancer specialists | Only for a complication | Treatment aims at remission |
Please read the last column as a general direction, not a promise. The type, the spread and your fitness change every case. The type is settled by a biopsy, and how far the cancer has spread is described in our post on small bowel cancer staging.
Send the tumour tests at the start, not after one treatment has failed. These tests pick the first medicine and can change it completely.
| Tumour type | Test | Why it matters |
|---|---|---|
| Adenocarcinoma | Mismatch repair (MMR) or MSI status | A tumour that lacks this repair system can respond very well to immunotherapy |
| Adenocarcinoma | Wider gene panel, including HER2, RAS and BRAF | Points to later options and clinical trials |
| GIST | KIT and PDGFRA gene change | Sets the imatinib dose and warns of resistance |
| Neuroendocrine tumour | Grade, and a scan that shows somatostatin receptors | Separates slow tumours that respond to injections from fast ones that need chemotherapy |
| Lymphoma | Exact subtype on the biopsy | Decides the drug combination |
These tests are done on the biopsy tissue. The tissue must be handled properly at the first biopsy, so the laboratory has enough to run them all. The types themselves are explained in our post on small bowel cancer types.
It is treated much like an aggressive bowel cancer. Chemotherapy with oxaliplatin and a fluoropyrimidine is the usual first choice, after the MMR test is known.
Small bowel adenocarcinoma is rare, so no large trial has settled the first treatment. Doctors use the experience from colon cancer and from smaller studies in the small bowel. Chemotherapy often shrinks the cancer for a time. A second drug combination is kept for when the first stops working.
Surgery has a limited role. A few deposits in the liver may be removed. The patient must be fit and the cancer must be responding. The team decides together. This rests on small series and not on a trial. So it is offered only to a few chosen patients, never as a routine.
Imatinib, a daily tablet, changed this disease. People who once lived only months now often live for years with tablet treatment.
| Step | Medicine | When it is used |
|---|---|---|
| First | Imatinib, with a higher dose for one particular KIT change | At the start, after the gene test |
| Second | Sunitinib | When imatinib stops working or cannot be tolerated |
| Third | Regorafenib | After the first two |
| Fourth | Ripretinib | After the earlier tablets have failed |
| Special case | Avapritinib | For one rare PDGFRA change that imatinib cannot touch |
The gene test decides the starting dose and warns of tumours that will not respond. A few GISTs lack the usual changes, and these respond poorly to tablets. They are referred to a specialist centre or a trial.
Surgery helps when the disease is stable or growing at only one spot while on tablets. It does not help when growth is widespread.
| Situation | Surgical role | Reason |
|---|---|---|
| Responding or stable on tablets | Consider removing the leftover disease | Takes out cells before resistance can appear |
| Growing at one spot only | Remove that spot and continue the tablet | One resistant clone is gone, the tablet still holds the rest |
| Growing in many places | Do not operate; change the tablet | An operation does not help and delays the next medicine |
| Bleeding, blockage or risk of rupture | Operate to relieve the problem | Controls the symptom and keeps treatment on track |
In every case surgery is added to the tablet and does not replace it. Deposits on the lining of the abdomen are common in GIST. They respond to imatinib, so tablets come first.
These tumours grow slowly, and even with liver deposits many people live for years. This slow pace justifies an active plan that includes surgery, which would not make sense in adenocarcinoma.
| Step | Treatment | Purpose |
|---|---|---|
| First | Long-acting somatostatin injections (octreotide or lanreotide) | Control symptoms and slow growth |
| If it grows | Targeted radiation with a radioactive-tagged medicine, called PRRT | Treats tumour cells that carry the receptor |
| Other | Everolimus tablets, or chemotherapy in selected cases | For tumours that keep growing |
| Fast-growing type | Platinum chemotherapy | Treats it like other fast cancers |
The aim is a good quality of life over years, not only a smaller tumour on a scan. A tumour that causes flushing and diarrhoea may need extra medicines. The heart is checked with an echo from time to time.
The small bowel lies in the middle of the abdomen, so spread to its lining is a typical pattern. How it is treated depends on the tumour type.
| Tumour type | How it behaves | Approach |
|---|---|---|
| Adenocarcinoma | Spreads aggressively, with a serious outlook | Chemotherapy; heated chemotherapy after surgery is investigational |
| GIST | Deposits are common but respond to tablets | Tablets first; remove leftover or single growing deposits |
| Neuroendocrine tumour | Slow disease on the bowel and mesentery | Reduce the bulk and use injections |
| Lymphoma | Involves the outer layer of the bowel | Drug treatment; surgery only for a complication |
Cytoreductive surgery with heated chemotherapy is known as HIPEC. It has been tried in small bowel adenocarcinoma, as in other bowel cancers. The evidence is limited to small selected groups, and it is not a standard treatment. It belongs in an expert unit, within a trial or registry. For most patients the default stays with medicines.
Even when lymphoma of the small bowel has spread, drugs are the treatment. Blood cancer specialists give them, and the aim is remission. The surgeon deals with complications.
The drug combination depends on the exact subtype. A bulky lymphoma can shrink fast, and the weakened bowel wall may then give way. So the surgeon stays involved during drug treatment.
Doctors ask whether the spread is limited to a few places, or widespread. A few places may allow local treatment. Widespread disease needs treatment of the whole body.
To define the extent, we need good CT or MRI scans. Some tumours need a special scan. A look with a laparoscope may be needed if the lining is suspected. An operation that was not needed brings risk without benefit. A debulking that was skipped can cost years in a neuroendocrine tumour.
Five questions, taken in order, lead to a plan that is made for you and not copied from a table.
The answers are discussed with a medical oncologist, and a radiologist and pathologist where needed. If a drug stops helping, or the cancer becomes removable, the plan changes. You will be told openly.
Some of the useful medicines are costly, and not every hospital offers every one. Ask early about what is available, so the plan is one you can follow.
| Item | What to ask |
|---|---|
| Tablets such as imatinib | Whether a trusted generic is available, and how long supplies last |
| Immunotherapy | Whether the tumour test supports it, and whether your insurer or a scheme covers it |
| PRRT | Which centres offer it, and how long the wait is |
| Scans and tests | Which are essential now, and which can wait |
| Travel | Whether some visits can be done by phone, with scans at a centre near home |
If you live far away, we can often plan scans and tests near your home and review the reports here. After the first stage of treatment, a follow-up schedule begins, as described in our post on follow-up and survivorship.
Ask each of these plainly. A good team will answer in simple words and will not hurry you.
Some patients first come with a different picture, a tumour that is large but has not spread. That plan is in our post on tumours too advanced to remove at once, and a tumour that can be removed is covered in our post on removable tumours.
It depends on the type of tumour. Adenocarcinoma is treated with chemotherapy, GIST with daily tablets, neuroendocrine tumour with injections and sometimes surgery, and lymphoma with drugs.
A biopsy for the exact type, then tumour tests. Adenocarcinoma needs a mismatch repair test, GIST needs a gene test, and a neuroendocrine tumour needs its grade and a receptor scan.
Yes, for adenocarcinoma whose cells lack the mismatch repair system. Such a tumour can respond well to pembrolizumab. The test decides this, so it is done before chemotherapy.
Sometimes. It is most useful for neuroendocrine tumours and for GIST that is stable on tablets. In adenocarcinoma it is for a few chosen patients or to relieve a blockage or bleeding.
No, not on your own. Stopping while the tumour is responding can let it grow again quickly. The tablet is paused or changed only on the advice of the treating team.
These tumours grow slowly, and many people live for years with treatment. Injections, targeted radiation and surgery are used in turn, with the aim of good quality of life.
It is investigational for small bowel adenocarcinoma. Evidence is limited to small groups, so it is considered only in expert units, usually within a trial.
For the full range of small bowel cancer care, start at the small bowel cancer treatment page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Has a scan shown that a small bowel cancer has reached the liver or the lining of the abdomen? Dr Harsh Shah will go through your reports. He will explain which treatment suits the tumour type, and what each step can and cannot do. Call, or message on WhatsApp. Call +91-63555-64601 Ask on WhatsApp
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.